Cargando…

Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC Cells

SIMPLE SUMMARY: The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains unfavorable among PDAC patients and is accompanied by high mortality rates. Cancer stem cells (CSCs) have a main role in PDAC aggressiveness. The present study sheds light on the molecular characterization of cancer ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Eptaminitaki, Giasemi C., Zaravinos, Apostolos, Stellas, Dimitris, Panagopoulou, Maria, Karaliota, Sevasti, Baltsavia, Ismini, Iliopoulos, Ioannis, Chatzaki, Ekaterini, Iliopoulos, Dimitrios, Baritaki, Stavroula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954787/
https://www.ncbi.nlm.nih.gov/pubmed/36831395
http://dx.doi.org/10.3390/cancers15041053
Descripción
Sumario:SIMPLE SUMMARY: The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains unfavorable among PDAC patients and is accompanied by high mortality rates. Cancer stem cells (CSCs) have a main role in PDAC aggressiveness. The present study sheds light on the molecular characterization of cancer stem-like subpopulations that significantly confer to PDAC aggressiveness and identifies CSC-specific lncRNA signatures with potential prognostic and therapeutic significance in PDAC. ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC), the second most prevalent gastrointestinal malignancy and the most common type of pancreatic cancer is linked with poor prognosis and, eventually, with high mortality rates. Early detection is seldom, while tumor heterogeneity and microarchitectural alterations benefit PDAC resistance to conventional therapeutics. Although emerging evidence suggest the core role of cancer stem cells (CSCs) in PDAC aggressiveness, unique stem signatures are poorly available, thus limiting the efforts of anti-CSC-targeted therapy. Herein, we report the findings of the first genome-wide analyses of mRNA/lncRNA transcriptome profiling and co-expression networks in PDAC cell line-derived CD133+/CD44+ cells, which were shown to bear a CSC-like phenotype in vitro and in vivo. Compared to CD133−/CD44− cells, the CD133+/CD44+ population demonstrated significant expression differences in both transcript pools. Using emerging bioinformatic tools, we performed lncRNA target coding gene prediction analysis, which revealed significant Gene Ontology (GO), pathway, and network enrichments in many dyregulated lncRNA nearby (cis or trans) mRNAs, with reported involvement in the regulation of CSC phenotype and functions. In this context, the construction of lncRNA/mRNA networks by ingenuity platforms identified the lncRNAs ATF2, CHEK1, DCAF8, and PAX8 to interact with “hub” SC-associated mRNAs. In addition, the expressions of the above lncRNAs retrieved by TCGA-normalized RNAseq gene expression data of PAAD were significantly correlated with clinicopathological features of PDAC, including tumor grade and stage, nodal metastasis, and overall survival. Overall, our findings shed light on the identification of CSC-specific lncRNA signatures with potential prognostic and therapeutic significance in PDAC.